NIH × Waldenstrom Macroglobulinemia × Dermatologic × Clear all
NCT01258998 2020-11-04

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled 8 charts
NCT01326702 2019-12-16

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
43 enrolled 18 charts
NCT00904514 2018-10-05

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

National Institutes of Health Clinical Center (CC)

Terminated
241 enrolled
NCT01567709 2018-04-11

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
NCT01254578 2017-09-25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
NCT00112723 2016-08-08

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Terminated
46 enrolled 12 charts
NCT00608361 2015-07-02

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
80 enrolled
NCT00002765 2015-04-29

Immunotoxin in Treating Patients With Leukemia or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
NCT00003210 2015-04-15

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

National Cancer Institute (NCI)

Phase 2 Completed
105 enrolled
NCT01158274 2014-11-07

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00890747 2014-03-17

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled
NCT00438958 2014-03-05

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

National Cancer Institute (NCI)

Phase 3 Completed
230 enrolled
NCT00096005 2014-02-24

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00499811 2014-02-24

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
NCT01016990 2014-01-10

Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Unknown
52 enrolled
NCT00769288 2014-01-07

FAU in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
NCT00293345 2013-09-30

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00324597 2013-09-17

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Unknown
18 enrolled
NCT00445497 2013-08-12

Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia

National Cancer Institute (NCI)

Phase 3 Unknown
400 enrolled
NCT00504205 2013-08-02

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

National Cancer Institute (NCI)

Phase NA Terminated
30 enrolled
NCT00103272 2013-06-04

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
74 enrolled
NCT00073944 2013-05-30

BCX-1777 in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00659568 2013-05-30

Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
28 enrolled
NCT00354185 2013-05-16

PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00348985 2013-05-03

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
55 enrolled
NCT00521430 2013-03-26

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

National Cancer Institute (NCI)

Phase NA Completed
30 enrolled
NCT00025415 2013-02-07

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled
NCT00089271 2013-01-25

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled
NCT00098891 2013-01-24

MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
NCT00734890 2012-03-16

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
18 enrolled
NCT00088868 2012-03-15

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
40 enrolled
NCT00589381 2012-03-08

Fenretinide Lym-X-Sorbâ„¢ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
30 enrolled
NCT01316744 2011-05-13

Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain

National Cancer Institute (NCI)

Phase 3 Unknown
214 enrolled